Results 241 to 250 of about 186,093 (261)

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Circulation, 2022
Carolyn S P Lam, Kelley R H Branch, Naveed Sattar   +2 more
exaly  

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin

Circulation, 2021
Koenraad Philippaert, Subha Kalyaanamoorthy, Shubham Soni   +2 more
exaly  

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Lancet, The, 2022
exaly  

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

Circulation, 2016
Bruce A Perkins, David H Fitchett, Mansoor Husain   +2 more
exaly  

Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology

Cell Metabolism, 2017
Eleuterio Ferrannini
exaly  

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Circulation, 2017
Mikhail N Kosiborod, Matthew A Cavender, Kamlesh Khunti   +2 more
exaly  

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

Circulation, 2017
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell   +2 more
exaly  

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

Circulation, 2019
Thomas A Zelniker, Itamar Raz, Erica L Goodrich   +2 more
exaly  

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Circulation, 2019
David D Berg, Benjamin M Scirica, Yared Gurmu   +2 more
exaly